Stereotactic Body Radiotherapy in Bulky Hepatocellular Carcinoma with or without Portal Vein Thrombosis: A Feasibility Review in an Egyptian Cohort

被引:0
|
作者
Hegazy, Mohamed Wahba [1 ]
Attallah, Hany [2 ]
El-Shahat, Khaled M. [3 ]
Mostafa, Emad [4 ]
Yassin, Adel [3 ]
Haggag, Ibraheem [4 ]
Fathy, Talaat [5 ]
Monem, Sameh M. Abdel [5 ]
Abdelmoaty, Ahmed [5 ]
Bessar, Ahmed A. [6 ]
机构
[1] Med Coll, Dept Clin Oncol & Nucl Med, Zagazig, Egypt
[2] Int Med Ctr IMC, Dept Radiat Oncol, Cairo, Egypt
[3] Al Azhar Coll Med, Dept Clin Oncol, Cairo, Egypt
[4] Int Med Ctr, Med Radiat Phys, Cairo, Egypt
[5] Coll Med, Trop Dept, Zagazig, Egypt
[6] Coll Med, Radiol Dept, Zagazig, Egypt
关键词
Stereotactic; Hepatocellular; Portal; Veins; Thrombosis; RADIATION-THERAPY; LIVER TOXICITY;
D O I
10.30476/mejc.2023.98866.1918
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) complicated by portal vein thrombosis presents significant clinical challenges. This study aims to retrospectively assess the feasibility of stereotactic irradiation for treating bulky HCC, with or without vascular invasion. Method: In this retrospective analysis, the radiotherapy treatment plans and clinical follow-up data of 22 patients diagnosed with HCC, with or without portal vein thrombosis, were reviewed. These patients underwent stereotactic body radiation therapy (SBRT) between September 2019 and September 2022. Treatment involved administering 40-50 Gy in 5 fractions using SBRT with volumetric modulated arc therapy (VMAT)/4D-computed tomography. Descriptive statistics were utilized without the application of statistical tests. Results: The mean age of the patients was 65 years, with 77% being male. Portal vein thrombosis was present in 73% of the cases, and the average tumor size was 7.2 cm (range 5-12 cm). 59% of patients were classified as Child -Pugh B. The median follow-up duration was 8 months (range 3-36 months). At 3 months, tumor response assessments revealed that 59% of patients had a partial response and 41% had stable disease; by 6 months, 37% achieved complete response, 26% maintained a partial response, and 37% had stable condition. Failure patterns included intrahepatic failure in two patients (at 7 and 9 months) and extrahepatic loss in two others (at 6 and 10 months). Radiation -induced liver disease occurred in two patients at 9- and 11 -weeks posttreatment, respectively. Liver cancer -specific mortality was 13.6%, while non -liver cancer -specific mortality stood at 9%. The progression -free survival rate was 82%. Conclusion: SBRT via VMAT represents a highly cost-effective, non-invasive local therapy with a favorable therapeutic ratio for treating bulky HCC cases, with or without vascular invasion.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [1] Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study
    Ji, Xiaoquan
    Xu, Zhe
    Sun, Jing
    Li, Wengang
    Duan, Xuezhang
    Wang, Quan
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [2] Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study
    Xiaoquan Ji
    Zhe Xu
    Jing Sun
    Wengang Li
    Xuezhang Duan
    Quan Wang
    Radiation Oncology, 18
  • [3] Stereotactic-body radiotherapy for portal vein tumor thrombosis in hepatocellular carcinoma patients
    Jeong, Bae Kwon
    Choi, Hoon Sik
    Kang, Ki Mun
    Jeong, Hojin
    Lee, Yun Hee
    Ha, In Bong
    Song, Jin Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis
    Yongjie Shui
    Wei Yu
    Xiaoqiu Ren
    Yinglu Guo
    Jing Xu
    Tao Ma
    Bicheng Zhang
    Jianjun Wu
    Qinghai Li
    Qiongge Hu
    Li Shen
    Xueli Bai
    Tingbo Liang
    Qichun Wei
    Radiation Oncology, 13
  • [5] Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis
    Shui, Yongjie
    Yu, Wei
    Ren, Xiaoqiu
    Guo, Yinglu
    Xu, Jing
    Ma, Tao
    Zhang, Bicheng
    Wu, Jianjun
    Li, Qinghai
    Hu, Qiongge
    Shen, Li
    Bai, Xueli
    Liang, Tingbo
    Wei, Qichun
    RADIATION ONCOLOGY, 2018, 13
  • [6] Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis
    Kang, Jingbo
    Nie, Qing
    Du, Rui
    Zhang, Liping
    Zhang, Jun
    Li, Qiliang
    Li, Jianguo
    Qi, Wenjie
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 43 - 50
  • [7] Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
    Li-Qing Li
    Ying Zhou
    Yong Huang
    Ping Liang
    Shi-Xiong Liang
    Ting-Shi Su
    Hepatology International, 2021, 15 : 630 - 641
  • [8] Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
    Li, Li-Qing
    Zhou, Ying
    Huang, Yong
    Liang, Ping
    Liang, Shi-Xiong
    Su, Ting-Shi
    HEPATOLOGY INTERNATIONAL, 2021, 15 (03) : 630 - 641
  • [9] Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis
    Xi, Mian
    Zhang, Li
    Zhao, Lei
    Li, Qiao-Qiao
    Guo, Su-Ping
    Feng, Zi-Zhen
    Deng, Xiao-Wu
    Huang, Xiao-Yan
    Liu, Meng-Zhong
    PLOS ONE, 2013, 8 (05):
  • [10] Radiotherapy for hepatocellular carcinoma with portal vein thrombosis: Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy
    Huang, Wen-Yen
    Yang, Jen-Fu
    Lo, Cheng-Hsiang
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 353 - 354